Cerebrospinal Fluid Total, Phosphorylated and Oligomeric A-Synuclein in Parkinson's Disease: A Systematic Review, Meta-Analysis and Meta-Regression Study

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Oct 26

PMID 39457579

Authors

Ioanna Kapsali

Maria-Evgenia Brinia

Vasilios C Constantinides

Affiliations

Soon will be listed here.

Abstract

: The diagnostic accuracy for Parkinson's disease (PD), a synucleinopathy, based on diagnostic criteria is suboptimal. A biomarker for synucleinopathies is pivotal both from a clinical and from a research point of view. CSF a-synuclein has been extensively studied over the past two decades as a candidate biomarker of synucleinopathies. Herein, we present data on studies focusing on total, phosphorylated and oligomeric CSF a-synuclein in PD. : Pubmed, Scopus and Web of Science were searched for studies with >10 PD patients and control subjects, with data (mean, SD) on total, phosphorylated or oligomeric a-synuclein. Cohen's , as a measure of effect size, was calculated for all a-synuclein forms. Subgroup analysis and meta-regression were performed in an effort to explain between-study heterogeneity. : Thirty studies on total, six studies on oligomeric and one study on phosphorylated a-synuclein were included. Total a-synuclein was decreased and oligomeric a-synuclein increased in PD patients vs. controls. The effect size was medium for total and high for oligomeric a-synuclein. A-syn forms provided suboptimal combined sensitivity/specificity for the differentiation of PD from controls. There was significant between-study heterogeneity. The PD cohort characteristics (sex, age, disease duration, UPDRS, H & Y) and study characteristics (study design, healthy vs. neurological controls, control for CSF blood contamination, method of a-syn measurement) could not account for between-study heterogeneity. Publication bias was limited. : CSF a-synuclein levels lack sufficient accuracy to be used as biomarkers for PD. The standardization of (pre)analytical variables may improve the discriminatory power of a-synuclein forms in the future.

References

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

Llorens F, Schmitz M, Varges D, Kruse N, Gotzmann N, Gmitterova K . Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol. 2016; 263(11):2271-2277. DOI: 10.1007/s00415-016-8259-0. View

Twelves D, Perkins K, Counsell C . Systematic review of incidence studies of Parkinson's disease. Mov Disord. 2003; 18(1):19-31. DOI: 10.1002/mds.10305. View

Spillantini M, Schmidt M, Lee V, Trojanowski J, Jakes R, Goedert M . Alpha-synuclein in Lewy bodies. Nature. 1997; 388(6645):839-40. DOI: 10.1038/42166. View

Shi M, Bradner J, Hancock A, Chung K, Quinn J, Peskind E . Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011; 69(3):570-80. PMC: 3117674. DOI: 10.1002/ana.22311. View

Lerche S, Wurster I, Roeben B, Zimmermann M, Riebenbauer B, Deuschle C . Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles. Mov Disord. 2019; 35(3):495-499. DOI: 10.1002/mds.27884. View

Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen A . Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012; 6(4):419-30. DOI: 10.2217/bmm.12.46. View

Li X, Yang W, Li X, Li X, Li W, Song Q . Phosphorylated Alpha-Synuclein in Red Blood Cells as a Potential Diagnostic Biomarker for Multiple System Atrophy: A Pilot Study. Parkinsons Dis. 2020; 2020:8740419. PMC: 7013322. DOI: 10.1155/2020/8740419. View

Yang L, Stewart T, Shi M, Pottiez G, Dator R, Wu R . An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression. Proteomics Clin Appl. 2017; 11(7-8). PMC: 5540649. DOI: 10.1002/prca.201700045. View

10.

Mollenhauer B, Zimmermann J, Sixel-Doring F, Focke N, Wicke T, Ebentheuer J . Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Disord. 2018; 34(1):67-77. DOI: 10.1002/mds.27492. View

11.

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

12.

Forland M, Ohrfelt A, Dalen I, Tysnes O, Blennow K, Zetterberg H . Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease. Parkinsonism Relat Disord. 2018; 49:4-8. DOI: 10.1016/j.parkreldis.2018.01.018. View

13.

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

14.

van Dijk K, Bidinosti M, Weiss A, Raijmakers P, Berendse H, van de Berg W . Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol. 2013; 21(3):388-94. DOI: 10.1111/ene.12176. View

15.

Shin J, Lee J, Kim Y, Shin S, Kim H, Nam H . Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. Neurology. 2020; 95(23):e3081-e3092. DOI: 10.1212/WNL.0000000000010942. View

16.

Constantinides V, Majbour N, Paraskevas G, Abdi I, Safieh-Garabedian B, Stefanis L . Cerebrospinal Fluid -Synuclein Species in Cognitive and Movements Disorders. Brain Sci. 2021; 11(1). PMC: 7830324. DOI: 10.3390/brainsci11010119. View

17.

Delgado-Alvarado M, Gago B, Gorostidi A, Jimenez-Urbieta H, Dacosta-Aguayo R, Navalpotro-Gomez I . Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. Mov Disord. 2017; 32(7):1066-1073. DOI: 10.1002/mds.27001. View

18.

Schlossmacher M, Mollenhauer B . Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials. Biomark Med. 2010; 4(5):647-50. DOI: 10.2217/bmm.10.93. View

19.

Wang F, Yu S, Zuo L, Cao C, Hu Y, Chen Z . Excessive Iron and α-Synuclein Oligomer in Brain are Relevant to Pure Apathy in Parkinson Disease. J Geriatr Psychiatry Neurol. 2016; 29(4):187-94. DOI: 10.1177/0891988716632918. View

20.

Xiang C, Cong S, Tan X, Ma S, Liu Y, Wang H . A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson's disease. NPJ Parkinsons Dis. 2022; 8(1):165. PMC: 9709054. DOI: 10.1038/s41531-022-00431-7. View